EARNEST Partners’s NovoCure NVCR Stock Holding History

EARNEST Partners’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-58	Closed	-$937	–	829
2023 Q3	$937	Hold	58	–	–	﹤0.01%	1075
2023 Q2	$2.41K	Hold	58	–	–	﹤0.01%	969
2023 Q1	$3.49K	Hold	58	–	–	﹤0.01%	875
2022 Q4	$4.25K	Hold	58	–	–	﹤0.01%	831
2022 Q3	$4K	Hold	58	–	–	﹤0.01%	842
2022 Q2	$4K	Hold	58	–	–	﹤0.01%	865
2022 Q1	$5K	Hold	58	–	–	﹤0.01%	850
2021 Q4	$4K	Hold	58	–	–	﹤0.01%	918
2021 Q3	$7K	Hold	58	–	–	﹤0.01%	758
2021 Q2	$13K	Hold	58	–	–	﹤0.01%	589
2021 Q1	$8K	Hold	58	–	–	﹤0.01%	707
2020 Q4	$10K	Hold	58	–	–	﹤0.01%	622
2020 Q3	$6K	Buy	+58	New	+$4.64K	﹤0.01%	712

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

EARNEST Partners's NVCR Position: Q4 2023 in Review

EARNEST Partners sold out of NovoCure (NVCR) in Q4 2023, closing a stake of 58 shares — an estimated $937 sold.

EARNEST Partners first reported a position in NVCR in Q3 2020 and held it in 13 quarters. The position peaked at $13K in Q2 2021. 219 funds tracked by Wall St. Rank hold NVCR as of Q4 2023.

EARNEST Partners reported no remaining NovoCure position as of Q4 2023 after selling out during the quarter.
EARNEST Partners sold 58 NovoCure shares in Q4 2023, an estimated $937.
EARNEST Partners first reported a position in NovoCure in Q3 2020 and held it in 13 quarters.
EARNEST Partners's NovoCure position peaked at $13K in Q2 2021.
219 funds tracked by Wall St. Rank held NovoCure as of Q4 2023.

Based on EARNEST Partners's 13F filing for Q4 2023, filed 14 Feb 2024.